Want to see TNGX full AI Analyst Report?
Top Page
Tango Therapeutics
(NASDAQ:TNGX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$23.50
▼(-5.13% Downside)
Action:Reiterated
Date:08/11/26
Overall score reflects a company with meaningful balance-sheet support and positive pipeline/capital-raise catalysts, but still constrained by very large losses and heavy cash burn. Technical indicators are broadly neutral and do not strongly reinforce upside momentum, while valuation metrics are weakened by negative earnings and no stated dividend support.
Positive Factors
Extended Funding Runway
The large capital raise materially reduces near- to medium-term financing risk and gives Tango resources to fund pivotal trials, R&D and commercialization preparation without immediately relying on additional financing.
Negative Factors
Heavy Cash Burn
Persistent, substantial cash consumption shows that operations are not self-funding and that Tango remains dependent on external capital. Even with an extended runway, continued development spending could require future financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended Funding Runway
The large capital raise materially reduces near- to medium-term financing risk and gives Tango resources to fund pivotal trials, R&D and commercialization preparation without immediately relying on additional financing.
Read all positive factors
Tango Therapeutics (TNGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.94B
Dividend YieldN/A
Average Volume (3M)4.03M
Price to Earnings (P/E)―
Beta (1Y)1.05
Revenue Growth121.47%
EPS Growth36.95%
CountryUS
Employees137
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.85
Shares Outstanding168,610,370
10 Day Avg. Volume2,102,693
30 Day Avg. Volume4,030,720
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)2.97
Price to Sales (P/S)16.50
P/FCF Ratio-7.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$44.40Price Target Upside79.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.39
Revenue Forecast (FY)N/A
Tango Therapeutics Business Overview & Revenue Model
Company Description
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine meth...
How the Company Makes Money
Tango Therapeutics primarily makes money through (1) collaboration and licensing revenue and (2) other partnership-related payments such as upfront fees, research funding reimbursements, and milestone payments tied to development, regulatory, and ...
Tango Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
66
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.81M | 62.38M | 42.07M | 36.53M | 24.86M | 37.04M |
| Gross Profit | 52.87M | 60.10M | 42.07M | 36.53M | 24.86M | 37.04M |
| EBITDA | -122.29M | -99.31M | -127.59M | -99.19M | -106.51M | -57.05M |
| Net Income | -123.72M | -101.59M | -130.30M | -101.74M | -108.18M | -58.23M |
Balance Sheet | ||||||
| Total Assets | 1.07B | 398.69M | 316.49M | 402.57M | 436.47M | 500.15M |
| Cash, Cash Equivalents and Short-Term Investments | 1.01B | 343.14M | 257.92M | 336.88M | 366.13M | 485.25M |
| Total Debt | 31.99M | 33.57M | 36.49M | 38.92M | 41.13M | 1.50M |
| Total Liabilities | 49.35M | 52.51M | 116.97M | 149.46M | 186.99M | 155.41M |
| Stockholders Equity | 1.02B | 346.18M | 199.52M | 253.11M | 249.48M | 344.75M |
Cash Flow | ||||||
| Free Cash Flow | -144.27M | -139.93M | -132.25M | -119.51M | -116.77M | -61.36M |
| Operating Cash Flow | -143.90M | -138.89M | -131.50M | -117.98M | -109.08M | -59.53M |
| Investing Cash Flow | -524.58M | -40.87M | 86.13M | 41.43M | 26.40M | -183.43M |
| Financing Cash Flow | 974.33M | 222.50M | 47.66M | 82.41M | 1.61M | 357.32M |
Tango Therapeutics Technical Analysis
Negative
24.77
Price Trends
27.62
Negative
25.99
Negative
19.31
Positive
Market Momentum
-1.03
Positive
35.14
Neutral
24.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNGX, the sentiment is Negative. The current price of 24.77 is below the 20-day moving average (MA) of 25.73, below the 50-day MA of 27.62, and above the 200-day MA of 19.31, indicating a neutral trend. The MACD of -1.03 indicates Positive momentum. The RSI at 35.14 is Neutral, neither overbought nor oversold. The STOCH value of 24.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TNGX.
Tango Therapeutics Risk Analysis
Tango Therapeutics disclosed 78 risk factors in its most recent earnings report. Tango Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tango Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $6.03B | -37.50 | -20.76% | ― | ― | 32.27% | |
52 Neutral | $3.94B | -26.87 | -25.74% | ― | 121.47% | 36.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $366.42M | -2.28 | -48.40% | ― | 15.98% | -40.75% | |
46 Neutral | $585.74M | -2.75 | -256.67% | ― | 4.08% | -343.67% | |
45 Neutral | $1.41B | -5.15 | -47.27% | ― | -65.40% | -164.71% | |
44 Neutral | $654.77M | -3.26 | -188.27% | ― | -17.90% | 32.10% |
* Healthcare Sector Average
TNGX
Tango Therapeutics
22.84
16.18
242.94%
ORKA
Oruka Therapeutics
92.62
77.06
495.24%
IMTX
Immatics
9.53
4.19
78.46%
SPRY
ARS Pharmaceuticals
6.00
-5.12
-46.04%
PRME
Prime Medicine, Inc.
3.59
0.47
15.06%
UPB
Upstream Bio, Inc.
6.62
-13.64
-67.32%
Tango Therapeutics Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Tango Therapeutics Expands At-The-Market Equity Program
Neutral
Aug 11, 2026
On November 21, 2025, Tango Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC for an at-the-market equity offering of up to $100 million in common stock, registered on a shelf registration statement. As of August 11, 2026...
Business Operations and StrategyExecutive/Board Changes
Tango Therapeutics Announces Executive Chair Barbara Weber’s Departure
Neutral
Aug 6, 2026
Tango Therapeutics disclosed that Dr. Barbara Weber’s employment as Executive Chair ended on August 3, 2026, in line with her amended employment agreement, and that she simultaneously resigned from all officer and board positions without any...
Business Operations and StrategyExecutive/Board Changes
Tango Therapeutics Adds Veteran Biopharma Leader to Board
Positive
Jun 23, 2026
On June 19, 2026, Tango Therapeutics expanded its board to seven members and appointed biopharmaceutical veteran Robert Azelby as an independent Class II director, with his term running until the 2029 annual meeting. Effective June 23, 2026, he al...
Business Operations and StrategyPrivate Placements and Financing
Tango Therapeutics Announces Major Underwritten Equity Offering
Positive
Jun 10, 2026
On June 9, 2026, Tango Therapeutics, Inc. entered into an underwriting agreement with a syndicate of banks for an underwritten offering of 18,166,667 shares of common stock and pre-funded warrants to purchase up to 1,833,395 additional shares, all...
Business Operations and Strategy
Tango Therapeutics Highlights Promising Vopimetostat Combination Data
Positive
Jun 8, 2026
On June 8, 2026, Tango Therapeutics reported positive initial safety and efficacy data from a Phase 1/2 trial of its PRMT5 inhibitor vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors in heavily pre-treated patients with MTA...
Executive/Board ChangesShareholder Meetings
Tango Therapeutics Holds 2026 Virtual Annual Stockholder Meeting
Positive
Jun 4, 2026
Tango Therapeutics held its 2026 annual meeting of stockholders in a virtual-only format on June 4, 2026, with 131,198,081 shares represented, or 90.96% of the 144,242,271 outstanding common shares entitled to vote as of the April 7, 2026 record d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.